Llama-Based Biotechnology Draws New Interest to Ablynx
This article is for subscribers only.
Ablynx NV is attracting interest from potential new partners eager to join the Belgian biotech company as it tries to harness antibodies from llamas for fighting disease.
Ablynx, which already has partnerships with AbbVie Inc. and Merck & Co. in the U.S. and other companies in Europe, has caught the eye of more potential partners as the Ghent-based company uses fragments of llama antibodies to develop proprietary therapeutic proteins called nanobodies, which have the potential to attack a range of human diseases.